Oxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3 

Oxford, UK, and San Jose, California, 22 June 2026 – Oxford BioTherapeutics (“OBT”), a clinical-stage oncology company specialising in proteomics-driven target discovery for antibody-based therapies enabled by its OGAP®-Verify platform, today announced two new clinical milestones with Boehringer Ingelheim-partnered programmes, BI 3820768 (OB33) and obrixtamig (OBT620).